Behind Gilead Sciences’ Dominance in HIV



Gilead’s market share in the HIV space

During the William Blair Growth Stock conference, Gilead Sciences (GILD) discussed the HIV (human immunodeficiency virus) population opportunity as well as its share in that market. According to WHO, ~35 million people globally are infected with HIV. In the US, the prevalence of the disease is ~1.2 million, and of this, ~1.1 million patients were diagnosed while ~800,000 initiated HIV medication.

Gilead’s share in terms of overall volume translates to ~78%, whereas 627,000 patients have remained on Gilead’s regimen.

Article continues below advertisement

During the first quarter of 2016, Gilead’s Atripla held a 7% share of naïve HIV patients, while Genvoya captured a 20% share. GILD’s dominance in the HIV space is visible from the data, which indicates that 76% of the naïve patients initiated therapy with Gilead drug. Gilead poses a strong competition to peers such as Pfizer (PFE), GlaxoSmithKline (GSK), and Johnson & Johnson (JNJ).

Gilead’s newly added TAF-based regimen

Gilead’s broad HIV portfolio includes Viread, Atripla, Truvada, Stribild, and Complera-Eviplera, along with the recently launched TAF (tenofovir alafenamide) combination regimen, which includes Genvoya, Descovy, and Odefsey.

In particular, Genvoya has reflected a very strong uptake since its launch and demonstrated to be one of the most successful launches in Gilead’s HIV franchise.

To avoid the direct risk of investing in Gilead, you can opt for ETFs like the iShares Nasdaq Biotechnology ETF (IBB), which has 8% weight in Gilead.

In the next part, we’ll discuss one of Gilead’s key HIV products.


More From Market Realist